eLIVE is a Laboratory Developed Test (LDT) that uses cytokine profiling from a live tumor biopsy to predict a patient's likelihood of response to an immune checkpoint inhibitor.

Currently, eLIVE is available to licensed healthcare professionals in the U.S. 

First time customer in the US? Contact us on elive@elephaslabs.com. 

Existing predictive biomarkers have shown limited accuracy. Many rely on fixed tissue, making it impossible to evaluate the dynamics of immune response to treatment. As a consequence, only 1 in 5 patients receiving ICI respond to therapy despite new drug approvals. 

eLIVE leverages the Elephas Live™ Platform to maintain live tumor tissue and microenviornment ex vivo. This approach provides a unique opportunity to assess dynamic immune response, providing deep datasets, robust clinical insights, and a prediction of response.

A laboratory developed test, or LDT, is a clinical test that is developed and used within a single laboratory that analyzes specimens from the human body to provide health information. LDTs are often developed in disease settings where a commercial test is not available. eLIVE tests a patient's tumor tissue to predict a patient's likelihood of reponse to immune checkpoint inhibition, and the test is performed within Elephas' certified CLIA laboratory.

eLIVE requires a fresh core needle biopsy, which can be obtained during a standard-of-care diagnostic procedure. Biopsies must be collected using 12- to 20-gauge probe, and be 10 mm or more in length.

Procure biopsy collection kit using the links on this page, or by contacting your account management team. The kit contains a specimen tube with a proprietary buffer to maintain tumor viability during transit. The tissue is placed directly into the tube following biopsy and then shipped overnight to our CLIA-certified lab in a temperature controlled shipping box.

Elephas has three ongoing clinical trials that are evaluating the concordance of the Elephas Live Platform with clinical response. Data suggests results from the platform are concordant with clinical responses. A preliminary readout of this data is available on our poster from SITC 2025.

eLIVE is indicated for patients with a suspected or confirmed solid tumor, who are candidates for ICI therapy and eligible for core needle biopsy. The test is intended to aid in the assessment of immune responsiveness to an ICIs and to support clinical decision making by a licensed physician in the context of other clinical, pathologic, and radiologic findings.

Request a new account by following the steps on this page [link to OMS].

You can order online (https://oms.elephas.com/) via our secure portal or download the test order form and send it via email or fax.

You will receive a tumor response profile with pathologist interpretation via our secure online portal within 14 days of biopsy reciept. You will receive an email when results are available.

A dedicated support team is available Monday through Friday from 8 a.m. to 6 p.m. U.S. Central Time. The team can be reached at 608-622-7954 or elive@elephas.com.